Subscribe to Updates for Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy

Stay informed about the latest developments in this trial. By subscribing, you will receive updates directly to your email. These updates will provide you with important information regarding any changes or progress related to the trial.